Chinmaya Rath
Corporate Officer/Principal chez GLYCOMIMETICS, INC.
Fortune : 43 679 $ au 31/05/2024
Profil
Chinmaya Rath is the founder of Cellurx.
He is currently the Director at Catena Biosciences, Inc., the Chief Business Officer & Senior Vice President at GlycoMimetics, Inc., and a Venture Partner at Social Impact Capital LLC.
He has an MBA from Warwick Business School and an undergraduate degree from Ravenshaw University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
0,25% | 12/01/2024 | 161 178 ( 0,25% ) | 43 679 $ | 31/05/2024 |
Postes actifs de Chinmaya Rath
| Sociétés | Poste | Début |
|---|---|---|
| GLYCOMIMETICS, INC. | Corporate Officer/Principal | - |
Catena Biosciences, Inc.
 Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Directeur/Membre du Conseil | - |
| Cellurx | Directeur Général | - |
Social Impact Capital, Inc.
 Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | Private Equity Investor | 01/11/2022 |
Formation de Chinmaya Rath
| Warwick Business School | Masters Business Admin |
| Ravenshaw University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Social Impact Capital, Inc.
Social Impact Capital, Inc. Investment ManagersFinance Social Impact Capital LLC (Social Impact) is a Venture Capital firm founded in 2015 by Sarah Cone. The firm is headquartered in New York. | Finance |
Catena Biosciences, Inc.
Catena Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Catena Biosciences, Inc. is an American biotech company that was founded in May 2021. The company is based in El Cerrito, CA. The company is based on technology developed in the Doudna and Francis labs at the University of California, Berkeley. Catena Biosciences' patented technology, called the Catenase platform, allows the construction of biomolecules that are currently unobtainable using modern manufacturing techniques. The platform has applications across multiple therapeutic areas, with an initial focus in oncology. The company is the recipient of an NIH SBIR grant and the American Cancer Society's BrightEdge Golden Ticket at UC's Bakar Labs. The company was founded in 2020 by Marco Lobba, Gregorio Guillen, Matthew B. Francis. Marco Lobba has been the CEO since 2020. | Commercial Services |
| Cellurx |
